Capital Advisors Ltd. LLC Has $655,000 Stock Holdings in AbbVie Inc. (NYSE:ABBV)

Capital Advisors Ltd. LLC boosted its holdings in AbbVie Inc. (NYSE:ABBV – Get Rating) by 14.9% during the 1st quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 4,043 shares of the company’s stock after acquiring an additional 525 shares during the quarter. Capital Advisors Ltd. LLC’s holdings in AbbVie were worth $655,000 at the end of the most recent quarter.

Other large investors have also added to or reduced their stakes in the company. Castle Financial & Retirement Planning Associates Inc. bought a new position in AbbVie in the 4th quarter valued at about $25,000. Intelligent Financial Strategies bought a new position in shares of AbbVie during the 4th quarter worth approximately $27,000. Psagot Value Holdings Ltd. Israel lifted its position in shares of AbbVie by 311.3% during the 4th quarter. Psagot Value Holdings Ltd. Israel now owns 4,360 shares of the company’s stock worth $28,000 after buying an additional 3,300 shares in the last quarter. Steward Financial Group LLC bought a new position in shares of AbbVie during the 4th quarter worth approximately $30,000. Finally, GoalVest Advisory LLC bought a new position in shares of AbbVie during the 1st quarter worth approximately $33,000. Institutional investors own 67.03% of the company’s stock.

Insider Buying and Selling at AbbVie

In other news, Vice Chairman Michael Severino sold 79,801 shares of AbbVie stock in a transaction on Monday, May 23rd. The stock was sold at an average price of $150.90, for a total transaction of $12,041,970.90. Following the completion of the transaction, the insider now owns 152,103 shares of the company’s stock, valued at approximately $22,952,342.70. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In related news, EVP Henry O. Gosebruch sold 83,960 shares of the business’s stock in a transaction that occurred on Monday, May 16th. The stock was sold at an average price of $155.00, for a total transaction of $13,013,800.00. Following the transaction, the executive vice president now directly owns 16,623 shares of the company’s stock, valued at approximately $2,576,565. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Vice Chairman Michael Severino sold 79,801 shares of the business’s stock in a transaction that occurred on Monday, May 23rd. The stock was sold at an average price of $150.90, for a total value of $12,041,970.90. Following the transaction, the insider now directly owns 152,103 shares in the company, valued at $22,952,342.70. The disclosure for this sale can be found here. Over the last quarter, insiders sold 363,761 shares of company stock valued at $55,528,771. 0.08% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

Several research firms have commented on ABBV. Daiwa Capital Markets cut shares of AbbVie from an “outperform” rating to a “neutral” rating and set a $150.00 target price on the stock. in a research report on Friday, May 6th. Morgan Stanley decreased their price target on shares of AbbVie from $191.00 to $188.00 and set an “overweight” rating for the company in a research note on Monday. UBS Group decreased their price target on shares of AbbVie from $154.00 to $146.00 and set a “neutral” rating for the company in a research note on Monday. The Goldman Sachs Group raised their price target on shares of AbbVie from $122.00 to $140.00 and gave the stock a “neutral” rating in a research note on Tuesday, April 12th. Finally, BMO Capital Markets raised their price target on shares of AbbVie from $161.00 to $174.00 and gave the stock an “outperform” rating in a research note on Monday, April 25th. One investment analyst has rated the stock with a sell rating, six have issued a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, AbbVie currently has an average rating of “Moderate Buy” and an average price target of $159.29.

AbbVie Price Performance

NYSE:ABBV traded down $0.68 during trading hours on Friday, reaching $138.24. 173,756 shares of the company were exchanged, compared to its average volume of 6,025,083. The company has a current ratio of 0.82, a quick ratio of 0.71 and a debt-to-equity ratio of 3.89. The stock’s 50-day moving average is $147.75 and its 200-day moving average is $150.05. The firm has a market cap of $244.29 billion, a PE ratio of 19.68, a price-to-earnings-growth ratio of 3.96 and a beta of 0.70. AbbVie Inc. has a twelve month low of $105.56 and a twelve month high of $175.91.

AbbVie (NYSE:ABBV – Get Rating) last announced its quarterly earnings data on Friday, July 29th. The company reported $3.37 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.31 by $0.06. AbbVie had a net margin of 22.03% and a return on equity of 157.31%. The firm had revenue of $14.58 billion during the quarter, compared to analyst estimates of $14.64 billion. During the same quarter in the prior year, the firm posted $3.11 earnings per share. AbbVie’s quarterly revenue was up 4.5% on a year-over-year basis. On average, sell-side analysts anticipate that AbbVie Inc. will post 14.05 earnings per share for the current fiscal year.

AbbVie Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Monday, August 15th. Investors of record on Friday, July 15th will be given a $1.41 dividend. The ex-dividend date is Thursday, July 14th. This represents a $5.64 dividend on an annualized basis and a yield of 4.08%. AbbVie’s dividend payout ratio (DPR) is 79.89%.

AbbVie Company Profile

(Get Rating)

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection.